IDEAS home Printed from https://ideas.repec.org/a/plo/pone00/0210179.html
   My bibliography  Save this article

Early treatment of acute hepatitis C infection is cost-effective in HIV-infected men-who-have-sex-with-men

Author

Listed:
  • Stephanie Popping
  • Sebastiaan J Hullegie
  • Anne Boerekamps
  • Bart J A Rijnders
  • Robert J de Knegt
  • Jürgen K Rockstroh
  • Annelies Verbon
  • Charles A B Boucher
  • Brooke E Nichols
  • David A M C van de Vijver

Abstract

Background: Treatment of hepatitis C virus infections (HCV) with direct acting antivirals (DAA) can prevent new infections since cured individuals cannot transmit HCV. However, as DAAs are expensive, many countries defer treatment to advances stages of fibrosis, which results in ongoing transmission. We assessed the epidemiological impact and cost-effectiveness of treatment initiation in different stages of infection in the Netherlands where the epidemic is mainly concentrated among HIV-infected MSMs. Methods: We calibrated a deterministic mathematical model to the Dutch HCV epidemic among HIV-infected MSM to compare three different DAA treatment scenarios: 1) immediate treatment, 2) treatment delayed to chronic infection allowing spontaneous clearance to occur, 3) treatment delayed until F2 fibrosis stage. All scenarios are simulated from 2015 onwards. Total costs, quality adjusted life years (QALY), incremental cost-effectiveness ratios (ICERs), and epidemiological impact were calculated from a providers perspective over a lifetime horizon. We used a DAA price of €35,000 and 3% discounting rates for cost and QALYs. Results: Immediate DAA treatment lowers the incidence from 1.2/100 person-years to 0.2/100 person-years (interquartile range 0.1–0.2) and the prevalence from 5.0/100 person-years to 0.5/100 person-years (0.4–0.6) after 20 years. Delayed treatment awaiting spontaneous clearance will result in a similar reduction. However, further delayed treatment to F2 will increases the incidence and prevalence. Earlier treatment will cost society €68.3 and €75.1 million over a lifetime for immediate and awaiting until the chronic stage, respectively. The cost will increase if treatment is further delayed until F2 to €98.4 million. Immediate treatment will prevent 7070 new infections and gains 3419 (3019–3854) QALYs compared to F2 treatment resulting in a cost saving ICER. Treatment in the chronic stage is however dominated. Conclusions: Early DAA treatment for HIV-infected MSM is an excellent and sustainable tool to meet the WHO goal of eliminating HCV in 2030.

Suggested Citation

  • Stephanie Popping & Sebastiaan J Hullegie & Anne Boerekamps & Bart J A Rijnders & Robert J de Knegt & Jürgen K Rockstroh & Annelies Verbon & Charles A B Boucher & Brooke E Nichols & David A M C van de, 2019. "Early treatment of acute hepatitis C infection is cost-effective in HIV-infected men-who-have-sex-with-men," PLOS ONE, Public Library of Science, vol. 14(1), pages 1-15, January.
    • Handle: RePEc:plo:pone00:0210179
    DOI: 10.1371/journal.pone.0210179
    as

    Download full text from publisher

    File URL: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0210179
    Download Restriction: no
    File URL: https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0210179&type=printable
    Download Restriction: no
    File URL: https://libkey.io/10.1371/journal.pone.0210179?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Richard Pitman & David Fisman & Gregory S. Zaric & Maarten Postma & Mirjam Kretzschmar & John Edmunds & Marc Brisson, 2012. "Dynamic Transmission Modeling," Medical Decision Making, , vol. 32(5), pages 712-721, September.
    2. Daniëla K van Santen & Anneke S de Vos & Amy Matser & Sophie B Willemse & Karen Lindenburg & Mirjam E E Kretzschmar & Maria Prins & G Ardine de Wit, 2016. "Cost-Effectiveness of Hepatitis C Treatment for People Who Inject Drugs and the Impact of the Type of Epidemic; Extrapolating from Amsterdam, the Netherlands," PLOS ONE, Public Library of Science, vol. 11(10), pages 1-18, October.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Jo-An Occhipinti & Danya Rose & Adam Skinner & Daniel Rock & Yun Ju C. Song & Ante Prodan & Sebastian Rosenberg & Louise Freebairn & Catherine Vacher & Ian B. Hickie, 2022. "Sound Decision Making in Uncertain Times: Can Systems Modelling Be Useful for Informing Policy and Planning for Suicide Prevention?," IJERPH, MDPI, vol. 19(3), pages 1-15, January.
    2. Klas Kellerborg & Werner Brouwer & Pieter Baal, 2020. "Costs and benefits of interventions aimed at major infectious disease threats: lessons from the literature," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 21(9), pages 1329-1350, December.
    3. Yin Liu & Hui Zhang & Lei Zhang & Xia Zou & Li Ling, 2020. "Economic Evaluation of Hepatitis C Treatment Extension to Acute Infection and Early-Stage Fibrosis Among Patients Who Inject Drugs in Developing Countries: A Case of China," IJERPH, MDPI, vol. 17(3), pages 1-13, January.
    4. Thomas E Delea & Derek Weycker & Mark Atwood & Dion Neame & Fabián P Alvarez & Evelyn Forget & Joanne M Langley & Ayman Chit, 2017. "Cost-effectiveness of alternate strategies for childhood immunization against meningococcal disease with monovalent and quadrivalent conjugate vaccines in Canada," PLOS ONE, Public Library of Science, vol. 12(5), pages 1-17, May.
    5. Matthew R Behrend & María-Gloria Basáñez & Jonathan I D Hamley & Travis C Porco & Wilma A Stolk & Martin Walker & Sake J de Vlas & for the NTD Modelling Consortium, 2020. "Modelling for policy: The five principles of the Neglected Tropical Diseases Modelling Consortium," PLOS Neglected Tropical Diseases, Public Library of Science, vol. 14(4), pages 1-17, April.
    6. Ashleigh R Tuite & Ann N Burchell & David N Fisman, 2014. "Cost-Effectiveness of Enhanced Syphilis Screening among HIV-Positive Men Who Have Sex with Men: A Microsimulation Model," PLOS ONE, Public Library of Science, vol. 9(7), pages 1-12, July.
    7. Anita W M Suijkerbuijk & Albert Jan van Hoek & Jelle Koopsen & Robert A de Man & Marie-Josee J Mangen & Hester E de Melker & Johan J Polder & G Ardine de Wit & Irene K Veldhuijzen, 2018. "Cost-effectiveness of screening for chronic hepatitis B and C among migrant populations in a low endemic country," PLOS ONE, Public Library of Science, vol. 13(11), pages 1-16, November.
    8. Léa Duchesne & Gilles Hejblum & Ndèye Coumba Toure Kane & Richard Njouom & Toni Thomas-d'Aquin & Raoul Moh & Babacar Sylla & Nicolas Rouveau & Alain Attia & Karine Lacombe, 2020. "Model-based cost-effectiveness estimates of testing strategies for diagnosing hepatitis C virus infection in people who use injecting drugs in Senegal," Post-Print hal-02543434, HAL.
    9. Pascal Crépey & Esther Redondo & Javier Díez-Domingo & Raúl Ortiz de Lejarazu & Federico Martinón-Torres & Ángel Gil de Miguel & Juan Luis López-Belmonte & Fabián P Alvarez & Hélène Bricout & Míriam S, 2020. "From trivalent to quadrivalent influenza vaccines: Public health and economic burden for different immunization strategies in Spain," PLOS ONE, Public Library of Science, vol. 15(5), pages 1-19, May.
    10. Richard E Nelson & Makoto Jones & Molly Leecaster & Matthew H Samore & William Ray & Angela Huttner & Benedikt Huttner & Karim Khader & Vanessa W Stevens & Dale Gerding & Marin L Schweizer & Michael A, 2016. "An Economic Analysis of Strategies to Control Clostridium Difficile Transmission and Infection Using an Agent-Based Simulation Model," PLOS ONE, Public Library of Science, vol. 11(3), pages 1-16, March.
    11. T I Armina Padmasawitri & Gerardus W Frederix & Bachti Alisjahbana & Olaf Klungel & Anke M Hövels, 2018. "Disparities in model-based cost-effectiveness analyses of tuberculosis diagnosis: A systematic review," PLOS ONE, Public Library of Science, vol. 13(5), pages 1-20, May.
    12. Ru Han & Clément François & Mondher Toumi, 2021. "Systematic Review of Health State Utility Values Used in European Pharmacoeconomic Evaluations for Chronic Hepatitis C: Impact on Cost-Effectiveness Results," Applied Health Economics and Health Policy, Springer, vol. 19(1), pages 29-44, January.
    13. Xiao Zang & Houlin Tang & Jeong Eun Min & Diane Gu & Julio S G Montaner & Zunyou Wu & Bohdan Nosyk, 2016. "Cost-Effectiveness of the ‘One4All’ HIV Linkage Intervention in Guangxi Zhuang Autonomous Region, China," PLOS ONE, Public Library of Science, vol. 11(11), pages 1-17, November.
    14. Beate Jahn & Sarah Friedrich & Joachim Behnke & Joachim Engel & Ursula Garczarek & Ralf Münnich & Markus Pauly & Adalbert Wilhelm & Olaf Wolkenhauer & Markus Zwick & Uwe Siebert & Tim Friede, 2022. "On the role of data, statistics and decisions in a pandemic," AStA Advances in Statistical Analysis, Springer;German Statistical Society, vol. 106(3), pages 349-382, September.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:plo:pone00:0210179. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: plosone (email available below). General contact details of provider: https://journals.plos.org/plosone/ .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.